Table 5.
Clinical Characteristics and Immunohistochemistry Staining of Thyroid Cancer Samples Used in This Study
| CSPG4 0% (n = 9) | CSPG4 ≥ 1% (n = 16) | p-Value | |
|---|---|---|---|
| Histology | 0.0168a | ||
| PTC | 7 (78%) | 4 (25%) | |
| ATC | 2 (22%) | 12 (75%) | |
| ICAM1 expression | >0.9999a | ||
| >1% | 9 (100%) | 16 (100%) | |
| ICAM1 pattern | 0.0168a | ||
| Apical | 7 (78%) | 4 (25%) | |
| Circumferential | 2 (22%) | 12 (75%) | |
| PDL1 expression | 0.4341a | ||
| >1% | 4 (44%) | 10 (63%) | |
| Clinical characteristics | |||
| Age | 44 (16–62) | 61 (26–86) | 0.0736b |
| Male sex | 0/9 (0%) | 5/16 (31%) | 0.0613a |
| Tumor size (cm) | 1.6 (0.5–4.8) | 3.7 (1.1–7.3) | 0.0035b |
| Lymph node metastases | 3/5 (60%) | 9/12 (75%) | 0.6000a |
| Distant metastases | 2/9 (22%) | 4/13 (31%) | >0.9999a |
| Lymphovascular invasion | 2/9 (22%) | 11/13 (85%) | 0.0073a |
| Extrathyroidal extension | 1/7 (14%) | 15/15 (100%) | <0.0001a |
| BRAFV600E mutationc | 7/8 (88%) | 6/10 (60%) | 0.3137a |
a
p-Values were determined using Fisher's exact test.
b
p-Values were determined using the Wilcoxon rank-sum test.
c
BRAFV600E mutational status was not assessed until 2010 at our institution.